Literature DB >> 27181454

Predicting anxiety responses to halogenated glucocorticoid drugs using the hexobarbital sleep time test.

Olga B Tseilikman1, Denis A Kozochkin1,2, Eugenia B Manukhina3,4, H Fred Downey4, Maria E Misharina2, Maria V Komelkova1,2, Anna A Nikitina1,2, Svyatoslav V Golodnii2, Margarita A Dodohova5, Vadim E Tseilikman1,2.   

Abstract

Glucocorticoids (GCs) are used to treat numerous diseases, but their use in limited by adverse side effects. One such effect is occasional increased anxiety. Since the intensity of hepatic microsomal oxidation has been shown to alter responses to GC, we examined the possibility that rats with lower rates of hepatic GC metabolism would have increased anxiety. We hypothesized that the resulting, excessive GC would stimulate brain monoamine oxidase A (MAO-A), which would reduce brain serotonin, and thereby increase anxiety. Hepatic microsomal oxidative intensity was evaluated by the hexobarbital sleep time (HST) test. Results showed that rats with lower rates of hepatic GC metabolism had elevated brain MAO-A activity, reduced brain serotonin, and more anxiety than rats with higher rates of hepatic GC metabolism. We suggest that the HST test, as an integrative test of microsomal oxidation status, should be useful for predicting individual sensitivity to GC and to other drugs metabolized by the hepatic microsomal oxidation system.

Entities:  

Keywords:  Anxiety; cytochrome P450; glucocorticoids; hexobarbital; monoamine oxidase A; serotonin

Mesh:

Substances:

Year:  2016        PMID: 27181454     DOI: 10.1080/10253890.2016.1183118

Source DB:  PubMed          Journal:  Stress        ISSN: 1025-3890            Impact factor:   3.493


  1 in total

1.  Hexobarbital Sleep Test for Predicting the Susceptibility or Resistance to Experimental Posttraumatic Stress Disorder.

Authors:  Maria Komelkova; Eugenia Manukhina; H Fred Downey; Alexey Sarapultsev; Olga Cherkasova; Viacheslav Kotomtsev; Pavel Platkovskiy; Stanislav Fedorov; Petr Sarapultsev; Olga Tseilikman; David Tseilikman; Vadim Tseilikman
Journal:  Int J Mol Sci       Date:  2020-08-17       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.